The Neuroimaging Core has experienced considerable growth and continuing productivity during the past funding cycle. The Core supports all routine clinical and research ADC neuroimaging examinations, funded imaging projects and scientific collaborations, and multi-institutional neuroimaging training. The Core has contributed to image acquisition, image registration, anatomical validation, and image analysis projects. Image analysis methods were extended from human imaging to transgenic mouse brain. Core resources were directly responsible for many ADC accomplishments by contributing to research teams innovative image analysis software and making the applications user friendly. Core's growth is in large measure attributable to the think tank atmosphere created by a dedicated multidisciplinary faculty. The proposed plan aims to continue Core's hardware and software support for research projects, development and validation of new MRI and PET imaging modalities for in vivo functional human imaging, routine post mortem MRI imaging, customized mouse imaging protocols that includes histological validation, uniform acquisition, investigator training, and quality control of all studies. These activities will improve the accuracy of AD diagnosis and lead to mechanistic models of brain changes in normal aging and dementia.

Public Health Relevance

The proposed plan for the Neuroimaging Core is to continue support for the clinical scanning of ADC patients and for research projects. The cores mission includes: development and validation of MRI and PET imaging modalities for in vivo functional human imaging. This is realized by routine post mortem MRI imaging with histological validation of imaging findings, correlated CSF studies, customized mouse MRI imaging protocols, uniform longitudinal scan acquisitions, investigator training, novel image analysis software development, and quality control of all studies. These activities will continue to improve the accuracy of the advance AD diagnosis and contribute to identifying and testing mechanisms of brain change in normal aging and dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG008051-24
Application #
8469379
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
24
Fiscal Year
2013
Total Cost
$177,526
Indirect Cost
$58,462
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960
Bonham, Luke W; Geier, Ethan G; Fan, Chun C et al. (2016) Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease. Ann Clin Transl Neurol 3:668-77
Brown, Ryan; Lakshmanan, Karthik; Madelin, Guillaume et al. (2016) A nested phosphorus and proton coil array for brain magnetic resonance imaging and spectroscopy. Neuroimage 124:602-11
Ting, Simon Kang Seng; Hao, Ying; Chia, Pei Shi et al. (2016) Clinicopathological correlation of psychosis and brain vascular changes in Alzheimer's disease. Sci Rep 6:20858
Fischer, Corinne E; Qian, Winnie; Schweizer, Tom A et al. (2016) Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease. J Alzheimers Dis 50:283-95
Karch, Celeste M; Ezerskiy, Lubov A; Bertelsen, Sarah et al. (2016) Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. PLoS One 11:e0148717
McCutcheon, Sarah T; Han, Dingfen; Troncoso, Juan et al. (2016) Clinicopathological correlates of depression in early Alzheimer's disease in the NACC. Int J Geriatr Psychiatry 31:1301-1311
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2016) Progression of Extrapyramidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates. J Alzheimers Dis 49:1085-93
Wisniewski, Thomas; Drummond, Eleanor (2016) Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines 15:401-15
Chapman, Kimberly R; Bing-Canar, Hanaan; Alosco, Michael L et al. (2016) Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. Alzheimers Res Ther 8:9

Showing the most recent 10 out of 444 publications